Influence of value of minimal residual disease at risk of developing recurrence of relapse in patients with acute lymphoblastic leukemia

Minimal residual disease (MRD) is the most significant predictor of the relapse in patients with acute lymphoblastic leukemia (ALL). MRD evaluation is necessary not only for the prediction of the relapse, but for additional stratification of patients by the risk groups in order to address the issue of the therapy individualization and to evaluate the therapy quality. This study analyzes the MRD parameters in patients with ALL at the stage of induction therapy and evaluates the effect of the value of the minimum residual disease on survival rates and the risk of relapse in patients with ALL treated according to protocol ALL-MB 2008.